Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 3/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.31 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8026526 | 0.79 | MEN1 (0.41) | LMNASMN1; SMN2MEN1CYP1A2KMT2A | |
| Hydrochloric Acid SCHEMBL17396300 | 0.78 | MEN1 (0.40) | LMNASMN1; SMN2MEN1CYP1A2KMT2A | |
| SCHEMBL18710561 | 0.77 | SIGMAR1 (0.33) | — | |
| SCHEMBL24240101 | 0.77 | SIGMAR1 (0.33) | — | |
| SCHEMBL24599246 | 0.76 | CA12 (0.35) | LMNASMN1; SMN2MEN1CYP1A2KMT2A | |
| SCHEMBL25194186 | 0.73 | — | — | |
| SCHEMBL11190991 | 0.72 | — | — | |
| SCHEMBL7765871 | 0.72 | — | — | |
| SCHEMBL1518838 | 0.72 | SIGMAR1 (0.43) | EPHX1 | |
| SCHEMBL12568711 | 0.70 | MEN1 (0.33) | SMN1; SMN2MEN1CYP1A2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150307526-A1 | Guanidine-Functionalized Particles and Methods of Making and Using | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2015-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150307526-A1 | Guanidine-Functionalized Particles and Methods of Making and Using | GMPS, GDA, RNMT | EPHX2 2262/4885LMNA 592/4885SMN1; SMN2 702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.